We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-10.7%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.35B
AUM Growth
-$119M
(-4.8%)
Cap. Flow
-$74.1M
Cap. Flow
% of AUM
-3.15%
Top 10 Holdings %
Top 10 Hldgs %
36.4%
Holding
125
New
15
Increased
30
Reduced
16
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$76.3M |
| 2 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$48.9M |
| 3 |
Editas Medicine
EDIT
|
+$44.9M |
| 4 |
Viatris
VTRS
|
+$37.5M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$36M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DYAX
DYAX CORPORATION
DYAX
|
+$84.3M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$53.5M |
| 3 |
Charles River Laboratories
CRL
|
+$30.3M |
| 4 |
GHDX
Genomic Health, Inc.
GHDX
|
+$28.5M |
| 5 |
Pacira BioSciences
PCRX
|
+$28.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 69.81% |
| 2 | Financials | 4.2% |
| 3 | Technology | 0.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $228M | 9.69% |
13,740,261
+2,055,460
| +18% | +$36M |
|
|
2
Viatris
VTRS
$20.1B
| $84.9M | 3.62% |
1,832,535
+776,535
| +74% | +$37.5M |
|
|
NXTM
3
DELISTED
NxStage Medical Inc.
NXTM
| $82.5M | 3.51% |
5,506,028
+917,028
| +20% | +$15.4M |
|
4
GSK
GSK
$104B
| $67.9M | 2.89% |
1,340,308
| – | – |
|
|
AET
5
DELISTED
Aetna Inc
AET
| $66.5M | 2.83% |
591,465
| – | – |
|
|
PTLA
6
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $63M | 2.68% |
3,089,785
+2,406,036
| +352% | +$76.3M |
|
|
AVXS
7
DELISTED
AveXis, Inc. Common Stock
AVXS
| $60.9M | 2.59% |
+2,236,701
| New | +$48.9M |
|
8
DaVita
DVA
$15.2B
| $60.3M | 2.57% |
822,000
| – | – |
|
|
9
Editas Medicine
EDIT
$457M
| $59M | 2.51% |
+1,709,400
| New | +$44.9M |
|
|
ADPT
10
DELISTED
Adeptus Health Inc
ADPT
| $53.1M | 2.26% |
956,533
-351,375
| -27% | -$18.2M |
|
|
XNPT
11
DELISTED
XENOPORT, INC.
XNPT
| $52.2M | 2.22% |
11,572,125
+5,284,751
| +84% | +$24.3M |
|
12
Vanda Pharmaceuticals
VNDA
$327M
| $50.1M | 2.13% |
5,996,691
| – | – |
|
|
GWPH
13
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $48.7M | 2.07% |
674,373
+364,251
| +117% | +$20M |
|
14
Xencor
XNCR
$1.3B
| $46.5M | 1.98% |
3,467,512
+2,210,900
| +176% | +$26.2M |
|
|
AAC
15
DELISTED
AAC Holdings
AAC
| $45.4M | 1.93% |
2,294,936
+512,842
| +29% | +$9.71M |
|
|
AVDL
16
DELISTED
Avadel Pharmaceuticals
AVDL
| $45M | 1.91% |
4,072,809
| – | – |
|
|
WBA
17
DELISTED
Walgreens Boots Alliance
WBA
| $43.1M | 1.83% |
511,457
+125,000
| +32% | +$9.98M |
|
|
UAM
18
DELISTED
Universal American Corp
UAM
| $37.7M | 1.61% |
5,285,500
+496,473
| +10% | +$3.22M |
|
|
SAGE
19
DELISTED
Sage Therapeutics
SAGE
| $35.7M | 1.52% |
1,113,654
+514,800
| +86% | +$18.1M |
|
|
AERI
20
DELISTED
Aerie Pharmaceuticals
AERI
| $32M | 1.36% |
2,632,482
+1,824,607
| +226% | +$28.9M |
|
21
eHealth
EHTH
$47.3M
| $30.7M | 1.31% |
3,264,588
| – | – |
|
|
ZLTQ
22
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| $30M | 1.28% |
+1,104,417
| New | +$26M |
|
|
ARRY
23
DELISTED
Array Biopharma Inc
ARRY
| $28.1M | 1.2% |
9,529,361
+800,000
| +9% | +$2.4M |
|
|
FPRX
24
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $27.6M | 1.18% |
680,000
| – | – |
|
25
McKesson
MCK
$98.5B
| $27.5M | 1.17% |
175,000
+30,354
| +21% | +$4.9M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q1 2016 Portfolio in Review
As of Q1 2016, Deerfield Management held 125 positions worth $2.35B, down 4.8% from $2.47B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Deerfield Management withdrew a net $74.1M in Q1 2016, closing 20 positions and reducing 16 holdings. Its most notable exit was DYAX CORPORATION, an estimated $84.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 68% a quarter earlier, followed by Financials and Technology.
Against the trend, Deerfield Management opened a new position in AveXis, Inc. Common Stock worth $60.9M.
- Deerfield Management's largest Q1 2016 buy was AveXis, Inc. Common Stock: 2,236,701 shares worth $60.9M.
- Deerfield Management added most to Portola Pharmaceuticals, Inc. in Q1 2016, an estimated $76.3M increase.
- Deerfield Management's biggest Q1 2016 reduction was Adeptus Health Inc, cutting an estimated $18.2M.
- Deerfield Management fully exited DYAX CORPORATION in Q1 2016, selling an estimated $84.3M.
- Deerfield Management's ten largest holdings make up 36% of its $2.35B portfolio in Q1 2016.
- Deerfield Management opened 15 new positions and closed 20 in Q1 2016.
- Deerfield Management's portfolio value fell 4.8% quarter-over-quarter to $2.35B.
Based on Deerfield Management's 13F filing for Q1 2016, filed 16 May 2016.